Learn about who we are, what we believe
and the people who lead us
Discover our unique scientific approach
for diseases with high unmet need.
The first and only FDA-approved
treatment for Demodex blepharitis
Explore the possibilities of our robust pipeline
to address significant unmet patient needs
Find additional corporate
and stock information.
Actual patients with Demodex blepharitis.
XDEMVY® (lotilaner ophthalmic solution) 0.25% is the first and only FDA-approved product for the millions of patients living with Demodex blepharitis.
Learn about XDEMVYImportant Safety Information:
Most common side effects: Most common side effect in clinical trials was stinging and burning in 10% patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Please see full Important Safety Information at XDEMVY.com.
We are focused on advancing a robust pipeline designed to address large diseases with limited treatment options.
View our pipelineOur scientific approach to creating new categories and our distinct culture are what set us apart.
Discover TarsusOur Terms of Use and Privacy Policy have changed.
By clicking accept, you agree that you have read and will abide by these new terms.
